Tillman Gerngross (Amagma)
January 18, 2022 08:00 AM ESTUpdated January 21, 02:06 AM
Startups
Deals

An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

Nicole DeFeudis

Editor

When Har­vard Med­ical School pro­fes­sor Leonard Zon told Dart­mouth pro­fes­sor and se­r­i­al en­tre­pre­neur Till­man Gern­gross he had a ques­tion, Gern­gross jok­ing­ly replied: “The an­swer is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times